NASDAQ:BIIBBiogen Stock Price, Forecast & News

Biogen's stock was trading at $294.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BIIB shares have decreased by 0.4% and is now trading at $293.22.
View which stocks have been most impacted by COVID-19.

31 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 4 sell ratings, 16 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Biogen.

Biogen is scheduled to release its next quarterly earnings announcement on Tuesday, October 27th 2020.
View our earnings forecast for Biogen.

Biogen Inc (NASDAQ:BIIB) released its earnings results on Wednesday, July, 22nd. The biotechnology company reported $10.26 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $8.03 by $2.23. The biotechnology company earned $3.68 billion during the quarter, compared to analyst estimates of $3.44 billion. Biogen had a return on equity of 50.10% and a net margin of 40.91%. During the same quarter last year, the firm posted $9.15 earnings per share.
View Biogen's earnings history.

Biogen announced that its board has authorized a share repurchase program on Monday, December 23rd 2019, which authorizes the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to buy shares of its stock through open market purchases. Stock buyback programs are often an indication that the company's board of directors believes its shares are undervalued.

Biogen updated its FY20 earnings guidance on Wednesday, July, 22nd. The company provided EPS guidance of $34.00-36.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $31.98. The company issued revenue guidance of $13.8-14.2 billion, compared to the consensus revenue estimate of $13.90 billion.

31 brokerages have issued 12-month price targets for Biogen's shares. Their forecasts range from $228.00 to $410.00. On average, they anticipate Biogen's stock price to reach $312.79 in the next year. This suggests a possible upside of 6.7% from the stock's current price.
View analysts' price targets for Biogen.

Media stories about BIIB stock have trended somewhat negative on Wednesday, according to InfoTrie. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Biogen earned a media sentiment score of -1.2 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about Biogen.

Biogen saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 3,600,000 shares, a decrease of 16.9% from the December 31st total of 4,330,000 shares. Based on an average daily trading volume, of 1,790,000 shares, the days-to-cover ratio is currently 2.0 days. Currently, 2.0% of the shares of the company are sold short.
View Biogen's Short Interest.

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Novavax (NVAX) and Repligen (RGEN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Walt Disney (DIS), Amgen (AMGN), Micron Technology (MU), Intel (INTC) and Boeing (BA).

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen's stock is owned by many different institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (1.46%), Goldman Sachs Group Inc. (0.84%), LSV Asset Management (0.64%), Sumitomo Mitsui Trust Holdings Inc. (0.48%), Swiss National Bank (0.43%) and Prudential Financial Inc. (0.32%). Company insiders that own Biogen stock include Alexander J Denner, Brian S Posner, Michael D Ehlers, Michel Vounatsos, Robert W Pangia and Stephen A Sherwin.
View institutional ownership trends for Biogen.

BIIB stock was sold by a variety of institutional investors in the last quarter, including Banco Santander S.A., Toronto Dominion Bank, Healthcare of Ontario Pension Plan Trust Fund, Bank of New York Mellon Corp, Russell Investments Group Ltd., First Trust Advisors LP, Montrusco Bolton Investments Inc., and LSV Asset Management. Company insiders that have sold Biogen company stock in the last year include Brian S Posner, and Stephen A Sherwin.
View insider buying and selling activity for Biogen.

BIIB stock was purchased by a variety of institutional investors in the last quarter, including AJO LP, Assetmark Inc., Assenagon Asset Management S.A., PGGM Investments, Robeco Institutional Asset Management B.V., SG Americas Securities LLC, MERIAN GLOBAL INVESTORS UK Ltd, and State of Michigan Retirement System. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner, and Michel Vounatsos.
View insider buying and selling activity for Biogen.

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BIIB stock can currently be purchased for approximately $293.22.

Biogen has a market capitalization of $46.42 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis. Biogen employs 7,400 workers across the globe.

The official website for Biogen is www.biogen.com.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]